Plasma cell‐rich acute rejections in living‐related kidney transplantation: a clinicopathological study of 50 cases. (31st July 2015)

• Record Type: Journal Article
• Authors: Abbas, Khawar; Mubarak, Muhammed; Zafar, Mirza N.; Aziz, Tahir; Abbas, Haider; Muzaffar, Rana; Rizvi, Syed A. H.
• Is Part Of: Clinical transplantation. Volume 29:Number 9(2015)
• Page Start: 835
• Page End: 841
• Publication Date: 2015-07-31
• Subjects: acute rejection -- graft outcome -- kidney transplant -- living related -- plasma cell‐rich infiltrates; Transplantation of organs, tissues, etc -- Periodicals; 617.95
• DOI: 10.1111/ctr.12589
• Languages: English
• ISSNs: 0902-0063

Abstract

Abstract: Background: Acute rejections (ARs) with plasma cell‐rich infiltrates (PCARs) are associated with poor outcomes. Patients and methods: Between February 2012 and December 2013, 1630 dysfunctional renal graft biopsies were performed. Of these, 50 (3%) showed PCAR. ARs with >10% plasma cells were defined as PCAR. Human leukocyte antigen (HLA) antibodies were tested in historic sera and at the time of PCAR. Treatment for PCAR comprised methylprednisolone, antithymocyte globulin, plasmapheresis, and anti‐CD20 antibody. Results: Of the 1630 dysfunctional biopsies, 50 (3%) had PCAR which occurred 3.1 ± 2.55 yr after transplant. The percentage of plasma cells was 28.8 ± 11.7, and CD138, 29.0 ± 12.4. Donor‐specific antibodies (DSAs) were found in 32 (64%) overall, Class I in 15% and Class II in 65%. Post‐treatment serum creatinine improved from 3.80 ± 2.59 to 2.66 ± 1.59 mg/dL in DSA positive (p < 0.003) and from 2.59 ± 1.09 to 2.08 ± 0.86 mg/dL in DSA negative (p < 0.008). One‐ and two‐yr graft survival after PCAR was 72%, 42% in the DSA‐positive vs. 89%, 82% in the DSA‐negative group, respectively (p = 0.071). Conclusions: Our results show that PCAR occurs late after transplant and in many cases is associated with DSAs. Graft outcome was poor when PCAR was associated with DSAs.